European Archives - Page 929 of 1290 - European Medical Journal

EMJ Oncology 6.1 2018

Supplemented by summaries of a selection of ESMO abstract presentations, EMJ’s Oncology eJournal provides a comprehensive summary of the 5 days in Munich…

First In-Human Study with GSK3359609, an Inducible T cell Costimulator Receptor Agonist in Patients with Advanced, Solid Tumours: Preliminary Results from INDUCE-1

Inducible T cell costimulator (ICOS), a member of the CD28/B7 receptor superfamily, is expressed on T cells after T cell receptor engagement with cognate…

Prof Ahmad Awada

Head of the Medical Oncology and Medicine Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium…

The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy

Adding a molecular perspective to the traditional multidisciplinary management of cancer patients is substantially hampering the adoption of precision…

Preliminary Safety, Efficacy, and Pharmacokinetic and Pharmacodynamic Characterisation from GARNET, a Phase I Clinical Trial of the Anti-PD-1 Monoclonal Antibody TSR-042 in Patients with Recurrent or Advanced Microsatellite Instability-High Endometrial Cancer

At the European Society for Medical Oncology (ESMO) 2018 Congress, data from the ongoing Phase I clinical trial of the anti-programmed death…

Prediction with Precision: Does TAILORx Make Chemotherapy a Personalised Treatment?

Adjuvant chemotherapy (CT) is commonly recommended to breast cancer patients following surgery. However, not all patients benefit from it, and the…

Congress Feature from ESMO 2018

During this year’s ESMO Congress, the EMJ team attended the three hotly- anticipated Presidential Symposia chaired by ESMO President Prof Josep Tabernero…

Patient Reports of Mouth Symptoms after Radiotherapy Treatment for Head and Neck Cancer: An International Survey

People with head and neck cancer frequently have symptoms that are caused by their disease or by their treatments, which may significantly impact on…

Genomic Profiling Clinical Trials in Cancer of Unknown Primary

Cancer of unknown primary (CUP) accounts for 3–5% of all cancers, and prognosis is poor for most patients, with a median survival of 6–9 months…

EMJ

Dr Mohammad Akheel

Consultant Head and Neck Oncosurgeon, Greater Kailash Hospitals, Indore, India…